Alzheimer amyloid protein precursor complexes with brain GTP-binding protein Go
…, Y Matsuura, S Takahashi, T Okamoto, Y Murayama… - Nature, 1993 - nature.com
THE most characteristic change in progressive dementia of Alzheimer's type is a tissue
deposit of amyloid β/A 4 protein 1 , which is derived from its precursor protein APP (ref. 2). …
deposit of amyloid β/A 4 protein 1 , which is derived from its precursor protein APP (ref. 2). …
CD4+ T-cell Immunity in the Peripheral Blood Correlates with Response to Anti-PD-1 Therapy
…, F Nishihara, Y Miura, K Hashimoto, Y Murayama… - Cancer immunology …, 2020 - AACR
Accumulating evidence indicates that CD8 + T cells in the tumor microenvironment and systemic
CD4 + T-cell immunity play an important role in mediating durable antitumor responses. …
CD4 + T-cell immunity play an important role in mediating durable antitumor responses. …
A simple structure encodes G protein-activating function of the IGF-II/mannose 6-phosphate receptor
T Okamoto, T Katada, Y Murayama, M Ui, E Ogata… - Cell, 1990 - cell.com
The insulin-like growth factor-IVmannose Gphosphate receptor (IGF-IllmanGPR) can
directly interact with and activate GIm2, a GTP binding protein (G protein). We found that the …
directly interact with and activate GIm2, a GTP binding protein (G protein). We found that the …
Identification of a Gs activator region of the β2-adrenergic receptor that is autoregulated via protein kinase A-dependent phosphorylation
T Okamoto, Y Murayama, Y Hayashi, M Inagaki… - Cell, 1991 - cell.com
We have localized a G protein activator region of the human BP-adrenergic receptor to region
pill-2 (from Argzs9 to LYS*‘~). The synthetic pill-2, corresponding to the C-terminal end of …
pill-2 (from Argzs9 to LYS*‘~). The synthetic pill-2, corresponding to the C-terminal end of …
Improved efficacy of ramucirumab plus docetaxel after nivolumab failure in previously treated non‐small cell lung cancer patients
…, T Uchida, Y Miura, F Nishihara, Y Murayama… - Thoracic …, 2019 - Wiley Online Library
Background It is unclear whether the chemotherapy response improves after exposure to
immunotherapy. Antiangiogenic agents have been shown to stimulate the immune system and …
immunotherapy. Antiangiogenic agents have been shown to stimulate the immune system and …
[HTML][HTML] Ligand-dependent G protein coupling function of amyloid transmembrane precursor
T Okamoto, S Takeda, Y Murayama, E Ogata… - Journal of Biological …, 1995 - Elsevier
Amyloid precursor protein (APP), a transmembrane precursor of β-amyloid, possesses a
function whereby it associates with G o through its cytoplasmic His 657 -Lys 676 . Here we …
function whereby it associates with G o through its cytoplasmic His 657 -Lys 676 . Here we …
[HTML][HTML] Potential of FDG-PET as prognostic significance after anti-PD-1 antibody against patients with previously treated non-small cell lung cancer
…, A Mouri, A Shiono, Y Miura, Y Murayama… - Journal of Clinical …, 2020 - mdpi.com
It remains unclear whether the accumulation of 2-deoxy-2-[ 18 F]fluoro-d-glucose ( 18 F-FDG)
before the initiation of anti-programmed death-1 (PD-1) antibody can predict the outcome …
before the initiation of anti-programmed death-1 (PD-1) antibody can predict the outcome …
Radiotherapy is an independent prognostic marker of favorable prognosis in non‐small cell lung cancer patients after treatment with the immune checkpoint inhibitor …
…, Y Miura, A Shiono, F Nishihara, Y Murayama… - Thoracic …, 2019 - Wiley Online Library
Background It remains unclear why radiation clinically provides a synergistic effect when
combined with immune checkpoint inhibitors such as nivolumab. The purpose of our study was …
combined with immune checkpoint inhibitors such as nivolumab. The purpose of our study was …
Reliability of the peptide nucleic acid‐locked nucleic acid polymerase chain reaction clamp‐based test for epidermal growth factor receptor mutations integrated into …
…, A Sutani, Huqun, K Udagawa, Y Murayama… - Cancer …, 2007 - Wiley Online Library
Gefitinib is an inhibitor of the tyrosine kinase activity of epidermal growth factor receptor (EGFR).
Accumulating evidence suggests that gefitinib may provide a survival benefit to EGFR …
Accumulating evidence suggests that gefitinib may provide a survival benefit to EGFR …
Peptide nucleic acid–locked nucleic acid polymerase chain reaction clamp‐based detection test for gefitinib‐refractory T790M epidermal growth factor receptor …
Mutations in the epidermal growth factor receptor (EGFR) are observed in a fraction of non‐small‐cell
lung cancers (NSCLS). EGFR mutation‐positive NSCLS responds to gefitinib. …
lung cancers (NSCLS). EGFR mutation‐positive NSCLS responds to gefitinib. …